Chemotherapy alone versus combined modality therapy for Stage III Hodgkin’s disease: A five-year follow-up of a Southwest Oncology Group study (SWOG-7518) USA

1985 ◽  
pp. 345-351 ◽  
Author(s):  
P. N. Grozea ◽  
E. J. Depersio ◽  
C. A. Coltman ◽  
C. J. Fabian ◽  
F. S. Morrison ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Combined Modality Therapy ◽  
Stage Iii ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Southwest Oncology Group ◽  
Combined Modality ◽  
Southwest Oncology Group Study

scholarly journals Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group Study

Cancer ◽  
1984 ◽  
Vol 54 (10) ◽  
pp. 2248-2256 ◽  
Author(s):  
Barth Hoogstraten ◽  
Nazli Gad-El-Mawla ◽  
Thomas R. Maloney ◽  
William S. Fletcher ◽  
Clarence B. Vaughn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Combined Modality Therapy ◽  
Oncology Group ◽  
Oncology Group Study ◽  
Southwest Oncology Group ◽  
Combined Modality ◽  
Southwest Oncology Group Study ◽  
First Recurrence

Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients.

1997 ◽  
Vol 15 (2) ◽  
pp. 518-527 ◽  
Author(s):  
E Salloum ◽  
D S Brandt ◽  
V J Caride ◽  
E Cornelius ◽  
D Zelterman ◽  
...  
Keyword(s):  
Predictive Value ◽  
Hodgkin's Disease ◽  
Progressive Disease ◽  
Residual Disease ◽  
Hodgkin’S Disease ◽  
Combined Modality Therapy ◽  
Stage I ◽  
Stage Iii ◽  
Disease Stage

PURPOSE To evaluate the utility of periodic gallium (67Ga) scans in the management of patients with Hodgkin's disease. PATIENTS AND METHODS From 1990 to 1994, 101 patients treated for Hodgkin's disease (stage I to II, n = 67; stage III to IV, n = 34) had a positive 67Ga scan at the time of diagnosis. Treatment included chemotherapy in 27 patients, radiation therapy in 28, and combined modality therapy in 46. All patients underwent 67Ga scans at the time of diagnosis, near the end or just after treatment, and at periodic follow-up evaluation. RESULTS After treatment, the 67Ga scan remained positive in four patients and was interpreted as negative in 97. Among the four patients with positive scans, two died of progressive disease and two relapsed. Among the remaining 97 patients with negative 67Ga scans, 16 patients relapsed, including five with stage I to II (7.5%) and 11 with stage III to IV (34.4%) disease. The negative predictive value of posttherapy 67Ga scan was 83.5% for all patients; however, when calculated according to stage, it was 92.4% for patients with stage I to II disease and 64.5% for patients with stage III to IV disease (P < .01). CONCLUSION A positive 67Ga scan at the end of therapy is rarely seen in patients with Hodgkin's disease and should be considered a manifestation of gross residual disease. However, a negative 67Ga scan after therapy had a significantly lower predictive value in patients with stage III to IV disease compared with stage I to II disease. The predictive value of 67Ga scans, as well as newer imaging studies, should be analyzed according to pretreatment stage.

Risk-Adapted, Combined-Modality Therapy With VAMP/COP and Response-Based, Involved-Field Radiation for Unfavorable Pediatric Hodgkin's Disease

2004 ◽  
Vol 22 (22) ◽  
pp. 4541-4550 ◽  
Author(s):  
Melissa M. Hudson ◽  
Matthew Krasin ◽  
Michael P. Link ◽  
Sarah S. Donaldson ◽  
Catherine Billups ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Combined Modality Therapy ◽  
Alkylating Agents ◽  
Stage I ◽  
Stage Iii ◽  
Combined Modality ◽  
Field Radiation ◽  
Involved Field

Purpose To evaluate the efficacy of vinblastine, doxorubicin, methotrexate, and prednisone (VAMP) and cyclophosphamide, vincristine, and procarbazine (COP) chemotherapy and response-based, involved-field radiation, a combined-modality regimen that limits doses of alkylating agents, anthracyclines, and radiation, in children with advanced and unfavorable Hodgkin's disease. Patients and Methods From 1993 to 2000, 159 children and adolescents with unfavorable Hodgkin's disease received three alternating cycles (total of six cycles) of VAMP/COP chemotherapy followed by response-based, involved-field radiation therapy: 15 Gy was administered to patients achieving a complete response, and 25.5 Gy was administered to those achieving a partial response after the first two cycles of chemotherapy and to all sites of bulky lymphadenopathy. Unfavorable disease was defined as clinical stage I and II with bulky peripheral nodal disease greater than 6 cm, initial bulky mediastinal mass 33% or more of the intrathoracic diameter, and/or “B” symptoms and all stage III and IV. Results Study enrollment was closed after an interim analysis estimated a 5-year event-free survival (EFS) rate below a predefined level. Disease presentation was localized (stage I/II) in 77 patients (48.4%) and advanced (stage III/IV) in 82 patients (51.6%). At a median follow-up of 5.8 years (range, 1.3 to 10.0 years), 38 patients had events, including relapse/progression (n = 35), second malignancy (n = 2), and accidental death (n = 1); nine relapses (25.7%) occurred greater than 4 years from diagnosis. Five-year survival and EFS estimates are 92.7% ± 2.5% and 75.6% ± 4.1%, respectively. Conclusion Risk-adapted combined-modality therapy with VAMP/COP and response-based, involved-field radiation therapy results in an unsatisfactory outcome for pediatric patients with unfavorable presentations of Hodgkin's disease.

Randomized phase III trial of chemoimmunotherapy in patients with previously untreated stage III, optimal disease ovarian cancer: A Southwest Oncology Group study

1989 ◽  
Vol 32 (1) ◽  
pp. 16-21 ◽  
Author(s):  
David S. Alberts ◽  
Nancy Mason-Liddil ◽  
Robert V. O'Toole ◽  
Thomas M. Abbott ◽  
Richard Kronmal ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Phase Iii ◽  
Stage Iii ◽  
Oncology Group ◽  
Phase Iii Trial ◽  
Oncology Group Study ◽  
Southwest Oncology Group ◽  
Southwest Oncology Group Study

Treatment of Unfavorable Childhood Hodgkin’s Disease With VEPA and Low-Dose, Involved-Field Radiation

2002 ◽  
Vol 20 (14) ◽  
pp. 3088-3094 ◽  
Author(s):  
Alison M. Friedmann ◽  
Melissa M. Hudson ◽  
Howard J. Weinstein ◽  
Sarah S. Donaldson ◽  
Larry Kun ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Low Dose ◽  
Hodgkin’S Disease ◽  
Combined Modality Therapy ◽  
Stage I ◽  
Stage Iii ◽  
Advanced Stage ◽  
Combined Modality ◽  
Field Radiation ◽  
Involved Field

PURPOSE: Between January 1990 and April 1993, 56 pediatric patients with Hodgkin’s disease were treated on a single-arm trial at three institutions with a regimen designed to maintain high cure rates while minimizing the potential late effects of treatment, such as infertility, second malignant neoplasms, and cardiopulmonary injury. PATIENTS AND METHODS: The regimen used combined-modality therapy with six cycles of vinblastine, etoposide, prednisone, and doxorubicin (VEPA) chemotherapy and low-dose, involved-field radiation. Unfavorable features comprised bulky presentations of localized (stage I or II) disease or advanced (stage III or IV) Hodgkin’s disease. RESULTS: Of 56 patients enrolled, 26 (46%) had unfavorable presentations of stage I/II disease and 30 (54%) had advanced (stage III/IV) disease. Seventy-nine percent of the patients are alive without disease at a median follow-up time of 8.9 years from diagnosis. Nineteen patients had events at a median of 1.5 years (range, 0.4 to 7.9 years) from diagnosis; 17 patients relapsed, one died of cardiomyopathy, and one died of accidental injuries. Survival and event-free survival (EFS) estimates at 5 years for the entire cohort were 81.9% (SE, 5.2%) and 67.8% (SE, 6.3%), respectively. Five-year EFS by stage was 100% for stage I, 79.2% (SE, 8.3%) for stage II, 70% (SE, 14.5%) for stage III, and 49.5% (SE, 11.3%) for stage IV patients. CONCLUSION: Combined-modality therapy with VEPA chemotherapy and low-dose, involved-field radiation is adequate for disease control of early-stage patients with unfavorable features, but it is inferior to other standard regimens for advanced-stage patients.

Sign in / Sign up

Export Citation Format

Share Document